Notice of Annual General Meeting in Karolinska Development AB (publ)
April 16, 2024 02:00 ET
|
Karolinska Development AB (publ)
The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Annual General Meeting, on Thursday May 16, 2024, at 3:00...
Sidetarde: 20% increase in revenue for Q1 2024, with SaaS subscriptions up 20%
April 16, 2024 01:46 ET
|
Sidetrade
Robust growth in bookings €3.98 million in New Annual Contract Value (ACV): up 117%With €1.85 million in SaaS bookings (ARR): up 108%And €2.13 million in Services bookings: up 127%Surge in the...
Interim report 2024, January - March
April 16, 2024 01:30 ET
|
HMS Networks AB
First quarter Net sales for the first quarter reached SEK 616 m (773), corresponding to a decrease of 20%. Currency translations had a negative effect of SEK 3 m on net salesOrder...
Agrify Corporation Reports Full-Year 2023 Earnings
April 15, 2024 17:42 ET
|
Agrify
Agrify Corporation Reports Full-Year 2023 Earnings - Company achieves first positive quarterly net income of approximately $572,000
Global Aerospace Jetstream Publication Offers Insight on Multi-Pronged, Collaborative Approach for Managing Claim Costs
April 15, 2024 11:47 ET
|
Global Aerospace Jetstream Publication
Morris Plains, April 15, 2024 (GLOBE NEWSWIRE) -- It is no secret that claim costs in the aviation industry have been rising steadily and significantly in the past few years. There are many reasons...
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
April 15, 2024 08:30 ET
|
Longeveron
Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer’s Disease has been accepted for two presentations at AAIC.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
April 15, 2024 08:05 ET
|
Organovo, Inc.
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Conte
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)
April 15, 2024 08:00 ET
|
Daxor Corporation
The Premier Event for Cardiovascular Industry Leaders and Clinicians Oak Ridge, TN, April 15, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
April 15, 2024 07:00 ET
|
Ultragenyx Pharmaceutical Inc.
Expansion Cohorts showed rapid, clinically meaningful improvement across multiple domains; improvements consistent or exceeding Dose-escalation Cohorts data at Day 170 Additional long-term data in...
Research: More than Half of Singapore’s Organisations Experienced 1-2 hours of Weekly Downtime Due to Fixed Line/ Fibre Network Failure Over the Last 12 months
April 14, 2024 16:30 ET
|
Cradlepoint
MELBOURNE, Australia, April 14, 2024 (GLOBE NEWSWIRE) -- Cradlepoint, part of Ericsson, the global leader in cloud-delivered LTE and 5G wireless network and security solutions, today announced...